<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lidocaine and hydrocortisone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lidocaine and hydrocortisone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lidocaine and hydrocortisone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11196" href="/d/html/11196.html" rel="external">see "Lidocaine and hydrocortisone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F188703"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ana-Lex;</li>
<li>Lidocort;</li>
<li>Radiaura</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F188715"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anesthetic/Corticosteroid;</li>
<li>
                        Antihemorrhoidal Agent</li></ul></div>
<div class="block doa drugH1Div" id="F188706"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cdbdbd76-6347-4313-a6cd-2664ff705009">Anti-inflammatory/anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory/anesthetic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical:</b> Apply twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal:</b> One applicatorful twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93c6026c-8da1-4676-a6b0-f8bf5611d875">Hemorrhoids, anorectal pain/itch</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemorrhoids, anorectal pain/itch:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Combine with dietary modifications, bowel hygiene, and warm sitz baths for best results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29420423','lexi-content-ref-35119707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29420423','lexi-content-ref-35119707'])">Ref</a></span>). General dosing guidelines provided; refer to specific product labeling for dosing instructions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical, rectal: </b>Apply to anal area or by applicator into rectum, as needed, up to 2 times daily. Some experts recommend limiting use to ≤1 week due to risk of mucosal thinning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bleday.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bleday.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990124"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987425"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F188707"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F56670798"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Burning sensation of skin (transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site erythema, localized blanching (lightening; application site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Transient stinging of skin</p></div>
<div class="block coi drugH1Div" id="F188698"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to lidocaine, hydrocortisone, local anesthetics of the amide type, corticosteroids, or any component of the formulation; tuberculous or fungal lesions; skin vaccinia, varicella, and acute herpes simplex infections.</p></div>
<div class="block war drugH1Div" id="F188684"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact dermatitis: Allergic contact dermatitis may occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Allergic and anaphylactic reactions may occur. Patients allergic to paraaminobenzoic acid derivatives (eg, procaine, tetracaine, benzocaine) have not shown cross sensitivity to lidocaine; use with caution in patients with a history of drug sensitivities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Local effects: Irritation, sensitivity, and/or infection may occur at the site of application; discontinue use and institute appropriate therapy if local effects occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause hypothalamic-pituitary-adrenal (HPA) axis suppression (reversible), manifestations of Cushing syndrome, hyperglycemia, or glycosuria; HPA axis suppression may lead to adrenal crisis. Absorption is increased by the use of occlusive dressings, application to abraded/fissured/irritated skin, prolonged use, or application to extensive or large surface areas. Patients who are acutely ill, debilitated, and/or elderly patients may be at increased risk of systemic toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution; acutely ill patients should be given reduced doses commensurate with their age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly.</p></div>
<div class="block foc drugH1Div" id="F188692"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, Rectal:</p>
<p style="text-indent:-2em;margin-left:4em;">Ana-Lex: Lidocaine hydrochloride 2% and hydrocortisone acetate 2% (4 g) [contains propylene glycol; kit contains 24 tubes (4 g each), single-use applicators, and wipes]</p>
<p style="text-indent:-2em;margin-left:4em;">Lidocort: Lidocaine hydrochloride 3% and hydrocortisone acetate 0.5% (85 g) [contains cetyl alcohol, methylparaben, propylene glycol, polyparaben]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Lidocaine hydrochloride 2% and hydrocortisone acetate 2% (7 g); Lidocaine hydrochloride 3% and hydrocortisone acetate 0.5% (7 g, 85 g); Lidocaine hydrochloride 3% and hydrocortisone acetate 1% (7 g)</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Radiaura: Lidocaine hydrochloride 3% and hydrocortisone acetate 0.5% [contains cetearyl alcohol, cetyl alcohol]</p>
<p style="text-indent:-2em;margin-left:2em;">Gel, Rectal:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Lidocaine hydrochloride 2.8% and hydrocortisone acetate 0.55% (100 g); Lidocaine hydrochloride 3% and hydrocortisone acetate 2.5% (7 g)</p></div>
<div class="block geq drugH1Div" id="F188681"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F188699"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lidocaine-Hydrocort (Perianal) External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3-0.5% (per gram): $1.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lidocaine-Hydrocortisone Ace External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1-1% (per gram): $48.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lidocort External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3-0.5% (per gram): $6.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Radiaura External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3-0.5% (per gram): $17.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Lidocaine-Hydrocortisone Ace Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.8-0.55% (per gram): $3.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Ana-Lex Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-2% (per each): $399.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lidocaine-Hydrocortisone Ace Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-2% (per each): $265.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3-0.5% (per each): $158.64 - $358.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3-1% (per each): $181.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3-2.5% (per each): $358.70 - $360.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F188695"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For external use only; not for oral, ophthalmic, otic, or nasal use.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical: Apply thin film to affected area.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Gently clean affected area (use cleansing wipe if provided). Attach applicator and gently squeeze tube until applicator is full and a small amount of cream comes out of the applicator opening. Applicator tip should be gently inserted into the anal area and squeeze tube until empty; an adequate amount to anal and peri-anal area will be applied via application tip by gently squeezing during application. Do not completely insert applicator and tube; do not insert deep in the anus or rectum.</p></div>
<div class="block use drugH1Div" id="F188694"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory/anesthetic: </b>Topical relief of pruritus, pruritic eczemas, abrasions, minor burns, radiation burns, inflammatory skin conditions, sun exposure, insect bites; pain, itching, soreness, and discomfort due to anal fissures, pruritus ani, pruritus vulvae, and similar conditions of the skin and mucous membranes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemorrhoids, anorectal pain/itch: </b>Itching, pain, soreness, and discomfort due to hemorrhoids.</p></div>
<div class="block mst drugH1Div" id="F54904970"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Medium, high, and very high potency topical corticosteroids, when used in neonates and infants &lt;1 year of age for diaper dermatitis, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of adrenal suppression; systemic absorption is higher in pediatric patients than adults (strong recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F188713"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F188687"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antiarrhythmic Agents (Class IB): Lidocaine (Topical) may enhance the adverse/toxic effect of Antiarrhythmic Agents (Class IB). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcipotriene: Hydrocortisone (Topical) may diminish the therapeutic effect of Calcipotriene.  Management: Monitor for reduced calcipotriene efficacy if combined with hydrocortisone valerate. Consider separating the administration of these agents by 10 to 12 hours to minimize the risk of this potential interaction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Lidocaine (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F188700"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted with this combination. See individual agents.</p></div>
<div class="block brc drugH1Div" id="F50473784"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if lidocaine or hydrocortisone is present in breast milk following use of this preparation. The manufacturer recommends that caution be exercised when administering lidocaine/hydrocortisone to breastfeeding women. See individual agents.</p></div>
<div class="block pha drugH1Div" id="F50473787"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine: Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.</p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone: Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties.</p></div>
<div class="block phk drugH1Div" id="F188697"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F46548731"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anacaine hc</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dolanal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Forproct</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Emorril | Lidocaina cloridrato e idrocortisone acetato</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ego soov it</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Anamantle hydrocortisone | Lidamantle hc | Lidazone | Lidocaine hcl hydrocortisone acetate | Lidocaine Hcl-Hydrocortisone Acetate | Lidocaine hydrocortisone | Lidocort | Peranex HC | Xyralid | Xyralid LP | Xyralid Rc</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ferziman hemorroidal</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Xyloproct</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Ana-Lex (hydrocortisone acetate and lidocaine hydrochloride) [prescribing information]. Alpharetta, GA: Avion Pharmaceuticals, LLC; October 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bleday.1">
<a name="Bleday.1"></a>Bleday R, Breen E. Home and office treatment of symptomatic hemorrhoids. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35119707">
<a name="35119707"></a>Brown S, Girling C, Thapa Magar H, et al. Guidelines, guidelines and more guidelines for haemorrhoid treatment: a review to sort the wheat from the chaff. <i>Colorectal Dis</i>. 2022;24(6):764-772. doi:10.1111/codi.16078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-and-hydrocortisone-drug-information/abstract-text/35119707/pubmed" id="35119707" target="_blank">35119707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29420423">
<a name="29420423"></a>Davis BR, Lee-Kong SA, Migaly J, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of hemorrhoids. <i>Dis Colon Rectum</i>. 2018;61(3):284-292. doi:10.1097/DCR.0000000000001030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-and-hydrocortisone-drug-information/abstract-text/29420423/pubmed" id="29420423" target="_blank">29420423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-and-hydrocortisone-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hydrocortisone acetate 0.55% and lidocaine hydrochloride 2.8% gel [prescribing information]. San Fernando, CA: PureTek Corporation; December 2018.</div>
</li>
<li>
<div class="reference">
                  Hydrocortisone acetate 2.5% and lidocaine hydrochloride 3% gel [prescribing information]. Manasquan, NJ: Seton Pharmaceuticals; February 2022.</div>
</li>
<li>
<div class="reference">
                  Hydrocortisone acetate 3% and lidocaine hydrochloride 1% cream [prescribing information]. San Fernando, CA: PureTek Corporation; December 2018.</div>
</li>
<li>
<div class="reference">
                  Lidocort (lidocaine and hydrocortisone) cream [prescribing information]. Panorama City, CA: PureTek Corporation; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-and-hydrocortisone-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Radiaura (hydrocortisone and lidocaine) [prescribing information]. San Fernando, CA: PureTek Corporation; received September 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10121 Version 195.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
